Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group-Reference-Cited by-同舟云学术

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Published:2019-01 Issue:3 Volume:102 Page:235-240
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Birgegard Gunnar¹^ORCID,Samuelsson Jan²,Ahlstrand Erik³,Ejerblad Elisabeth¹,Enevold Christian⁴,Ghanima Waleed⁵,Hasselbalch Hans⁶,Nielsen Claus H.⁶,Knutsen Håvar⁷,Pedersen Ole B.⁸,Sørensen Anders⁴⁶,Andreasson Björn⁹^ORCID

Affiliation:

1. Department of Medical Sciences Uppsala University Uppsala Sweden

2. Department of Hematology University Hospital Linkoping Linkoping Sweden

3. Department of Medicine, Faculty of Medicine and Health Örebro University Örebro Sweden

4. Institute for Inflammation Research Copenhagen University Hospital Copenhagen Denmark

5. Department of Research Østfold Hospital Sarpsborg Norway

6. Department of Hematology Zealand University Hospital Roskilde Denmark

7. Department of Hematology Ullevål Hospital Oslo Norway

8. Department of Clinical Immunology Næstved Hospital Næstved Denmark

9. Hematology Section, Specialist Medicine NU Hospital Group Uddevalla Sweden

Funder

Nordic Study Group for Myeloproliferative Neoplasms (NMPN)

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13198

Reference24 articles.

1. Use of the Functional Assessment of Cancer Therapy−Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

2. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

3. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

4. Long-term results of prednisone treatment for the anemia of myelofibrosis

5. Alleviating anemia and thrombocytopenia in myelofibrosis patients

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MoReLife – real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients;Annals of Hematology;2024-07-29

2. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM;Future Oncology;2024-07-29

3. Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib;Annals of Hematology;2024-06-12

4. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis;Cancers;2023-12-28

5. Nutrition in chronic inflammatory conditions: Bypassing the mucosal block for micronutrients;Allergy;2023-12-12